Abstract
Cardiotoxicity (CTX) remains a clinically significant side effect of anti-HER2 therapies. Trastuzumab-related cardiotoxicity is most often manifested by an asymptomatic decrease in left ventricular ejection fraction (LVEF) and less often by clinical heart failure. The aim of this study is to demonstrate the trastuzumab cardiotoxicity with cardiac marker changing and efficacy of steroid and intravenous immunoglobulin (ivig) therapy in the prevention of cardiotoxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
